Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Summary

This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.

Timeline

Start

2020-06-02

Primary completion

2022-06

Completion

2028-03

Publications

• Corro C, Buchs NC, Tihy M, Durham-Faivre A, Bichard P, Frossard JL, Puppa G, McKee T, Roth A, Zilli T, Trembleau C, Di Marco M, Dutoit V, Dietrich PY, Ris F, Koessler T. Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer. BMC Cancer. 2022 Jul 15;22(1):772. doi: 10.1186/s12885-022-09820-w.

Drugs

Indications